

BIOMÉRIEUX

# VITEK® REVEAL™

FAST AST FOR BLOODSTREAM INFECTIONS




PIONEERING DIAGNOSTICS

EVERY 2.8 SECONDS SOMEONE DIES FROM<sup>1</sup>

# SEPSIS



FAST AST  
**VITEK® REVEAL™**



**MODULAR TO FIT ANY LAB**

**MORTALITY ODDS INCREASE**

**9% EVERY HOUR** 



**BETWEEN PRESENTATION  
& ANTIBIOTIC  
ADMINISTRATION**

**IN PATIENTS WITH SEPSIS<sup>2</sup>**

## FAST

- Results in an average of 5.5-6 hours and as early 3 hours<sup>3,4</sup>
- Direct from positive blood culture

## ACTIONABLE

- Wide antimicrobial coverage for gram-negative bloodstream infections
- Allows faster antimicrobial therapy de-escalation to support antimicrobial stewardship
- Real-time monitoring of minimum inhibitory concentration (MIC) results

## INTEGRATED

- Fully integrated within the bioMérieux Sepsis Solution
- Access bioMérieux services, including consultancy to education
- Bi-directional connectivity with MAESTRIA™

# THE BIOMÉRIEUX TOTAL SEPSIS SOLUTION

VITEK® REVEAL™ integrates seamlessly within the sepsis care workflow.



©2024 bioMérieux, Inc. • BACT/ALERT, BIOFIRE, BIOMÉRIEUX, the BIOMÉRIEUX logo, CLARION, MAESTRIA, REVEAL, VIRTUO, and VITEK are used pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies • Patents: www.biomerieux-usa.com/patents • PRN 070169 Rev.01A

†FDA CLEARED | CE 2797

#### SOURCES

1. What is Sepsis? - World Sepsis Day - September 13  
<https://www.worldsepsisday.org/sepsis>
2. Liu VX et al. Am J Respir Crit Care Med. 2017. Vol 196,(7): 856–863
3. Rottman et al., ECCMID 2022.
4. BMX.1.129899 Clinical Trial Summary Report (proprietary, on file at bioMérieux).